/images/ppid_59c68470-image-17696000282438319.webp)
/images/ppid_59c68470-image-176959752861837823.webp)
/images/ppid_59c68470-image-176959753355571396.webp)
What is the story about?
Thyrocare Technologies reported a strong performance for the December quarter, with net profit rising 36.7% year-on-year to ₹26.1 crore, compared with ₹19.1 crore in the same period last year, aided by higher volumes and operating leverage
Revenue from operations grew 19.3% YoY to ₹182 crore in Q3, up from ₹152.5 crore a year ago. Operating performance improved sharply, with EBITDA surging 46.7% YoY to ₹58.3 crore, compared with ₹39.7 crore in the year-ago quarter.
As a result, EBITDA margin expanded to 32% from 26% last year, reflecting better cost efficiencies and scale benefits
On a sequential basis, profit before tax stood at ₹36.6 crore, while the quarter included exceptional items of ₹6 crore, largely linked to the impact of new labour codes and one-time capital restructuring costs, the company said in its exchange filing
For the nine months ended December 31, 2025, Thyrocare reported a net profit of ₹105.2 crore, compared with ₹74 crore in the year-ago period, while revenue rose to ₹563.6 crore from ₹459.2 crore last year
Diagnostic Testing Services remains the largest segment, reporting revenue of ₹182.4 crore in Q3, up from ₹151.9 crore a year ago. It delivered segment profit before tax of ₹36.8 crore, reflecting strong operating leverage. The Imaging Services segment reported revenue of ₹12.4 crore in the quarter, broadly stable year-on-year, but continued to post a marginal segment loss of ₹1.1 crore, indicating pressure on profitability.
Overall, the sharp improvement in margins was led by diagnostics, which continues to account for the bulk of revenues and profits for the company
Shares of Thyrocare Technologies Ltd ended 458.10 ahead of the result announcement.
Revenue from operations grew 19.3% YoY to ₹182 crore in Q3, up from ₹152.5 crore a year ago. Operating performance improved sharply, with EBITDA surging 46.7% YoY to ₹58.3 crore, compared with ₹39.7 crore in the year-ago quarter.
As a result, EBITDA margin expanded to 32% from 26% last year, reflecting better cost efficiencies and scale benefits
On a sequential basis, profit before tax stood at ₹36.6 crore, while the quarter included exceptional items of ₹6 crore, largely linked to the impact of new labour codes and one-time capital restructuring costs, the company said in its exchange filing
For the nine months ended December 31, 2025, Thyrocare reported a net profit of ₹105.2 crore, compared with ₹74 crore in the year-ago period, while revenue rose to ₹563.6 crore from ₹459.2 crore last year
Diagnostic Testing Services remains the largest segment, reporting revenue of ₹182.4 crore in Q3, up from ₹151.9 crore a year ago. It delivered segment profit before tax of ₹36.8 crore, reflecting strong operating leverage. The Imaging Services segment reported revenue of ₹12.4 crore in the quarter, broadly stable year-on-year, but continued to post a marginal segment loss of ₹1.1 crore, indicating pressure on profitability.
Overall, the sharp improvement in margins was led by diagnostics, which continues to account for the bulk of revenues and profits for the company
Shares of Thyrocare Technologies Ltd ended 458.10 ahead of the result announcement.
